Pfizer Research Grant for Non-Hemophilic Bleeding Disorders

This Pfizer research grant programme supports early-stage scientific investigations into the role of Tissue Factor Pathway Inhibitor (TFPI) modulation in bleeding disorders beyond hemophilia.

The initiative aims to:

• Address gaps in understanding hemostatic rebalancing mechanisms
• Explore new therapeutic pathways for rare bleeding disorders
• Support pre-clinical and basic science research
• Advance knowledge of coagulation biology

Key Research Focus Areas

The programme supports studies on:

• Anti-TFPI-mediated hemostatic rebalancing
• TFPI modulation mechanisms
• Thrombin generation impairment
• Inherited bleeding disorders
• Non-hemophilic bleeding conditions
• Rare clotting factor deficiencies
• von Willebrand disease
• Glanzmann’s thrombasthenia
• Bleeding disorders of unknown cause

Research Objectives

Funded projects should aim to:

• Generate pre-clinical and basic science data
• Investigate coagulation pathway dysfunction
• Explore therapeutic potential of TFPI modulation
• Improve understanding of rare bleeding disorders
• Identify novel mechanisms of impaired hemostasis

Funding Details

• Maximum grant amount: USD 50,000 per project
• Project duration: Up to 1 year
• Type of support: Competitive research funding

Eligible Applicants

Applications are open to:

• Research institutions and universities
• Medical and scientific organizations
• Eligible institutions in approved regions

Eligible Regions

• Brazil
• China
• Europe
• Israel
• Japan
• Saudi Arabia
• South Korea
• Turkey
• United States

Investigator Requirements

Principal investigators must hold relevant qualifications such as:

• Medical degrees (MD)
• Doctoral degrees (PhD)
• Nursing qualifications
• Pharmacy qualifications
• Physiotherapy qualifications
• Social work qualifications

Applicants must be affiliated with eligible institutions capable of receiving Pfizer funding.

Key Conditions

• Projects must be pre-clinical or foundational research
• Focus must be non-hemophilic bleeding disorders
• Research must be scientifically justified and hypothesis-driven
• Institutions must be legally able to receive grant funds directly from Pfizer

How to Apply

Applicants should:

1. Develop a pre-clinical research proposal aligned with TFPI modulation
2. Ensure institutional eligibility
3. Confirm principal investigator qualifications
4. Submit a detailed scientific study plan
5. Apply through Pfizer’s competitive grant process

Strong proposals typically include:

• Clear scientific hypothesis
• Strong experimental design
• Relevance to rare bleeding disorders
• Potential therapeutic insights
• Feasible one-year research plan

Tips for Applicants

To improve success chances:

• Focus on mechanistic insights into coagulation pathways
• Clearly define research questions and endpoints
• Emphasise novelty in TFPI modulation research
• Ensure strong pre-clinical methodology
• Align with rare disease research priorities

Avoid proposals that lack clear mechanistic focus or are not pre-clinical in nature.

FAQ

Who can apply?

Eligible research institutions in approved countries can apply, with qualified principal investigators.

What is the funding amount?

Up to USD 50,000 per project.

What is the project duration?

Projects must be completed within one year.

What diseases are included?

Non-hemophilic bleeding disorders such as von Willebrand disease, Glanzmann’s thrombasthenia, and rare clotting factor deficiencies.

What is the main research focus?

Anti-TFPI-mediated hemostatic rebalancing mechanisms.

Is clinical research allowed?

No. The programme focuses on pre-clinical and foundational research.

Conclusion

The Pfizer competitive research grant programme supports early-stage scientific exploration of TFPI modulation in non-hemophilic bleeding disorders. By funding pre-clinical investigations, the initiative aims to advance understanding of rare bleeding conditions and support the development of future therapeutic strategies.